Literature DB >> 28556957

Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis.

Anna Caliò1, Veronica Lever1, Andrea Rossi2, Eliana Gilioli1, Matteo Brunelli1, Alessandra Dubini3, Sara Tomassetti4, Sara Piciucchi5, Alessia Nottegar1, Giulio Rossi6, Marianne Kambouchner7, Alessandra Cancellieri8, Mattia Barbareschi9, Giuseppe Pelosi10, Claudio Doglioni11, Alberto Cavazza12, Rodolfo Carella13, Paolo Graziano14, Bruno Murer15, Venerino Poletti4, Marco Chilosi1,16.   

Abstract

AIMS: The association between lung cancer and idiopathic pulmonary fibrosis (IPF) is well known, but the significance of this association is poorly understood. Bronchiolar honeycomb cysts have been proposed as possible precursors for the development of carcinoma, but limited evidence in support of this hypothesis is available. The aim of this study was to investigate this hypothesis analysing a series of carcinomas arising in IPF by immunohistochemistry. METHODS AND
RESULTS: Thirty-three lung carcinomas arising in patients with IPF were analysed with a panel of immunohistochemical markers. The antibodies included those against pneumocyte markers [thyroid transcription factor 1 (TTF1), napsin-A, and surfactant protein A], the goblet cell marker mucin 5AC, markers of basal/squamous cell differentiation [cytokeratin (CK) 5/6 and ΔN-p63], and markers related to enteric differentiation (CDX2, mucin 2, CK20, and villin). A series of 100 consecutive lung adenocarcinomas arising in smokers without IPF were investigated as controls. All carcinomas arising in IPF patients were peripherally located on imaging analysis. The diagnoses were: eight squamous cell carcinomas, 20 adenocarcinomas, three small-cell carcinomas (including one composite small-cell carcinoma and adenocarcinoma), and two large-cell carcinomas. Among adenocarcinomas, a 'pneumocyte' profile (TTF1/napsin-A/SPA1-triple-positive) was observed in seven of 20 (35% versus 84% in non-IPF controls, P = 0.0001). The remaining 13 adenocarcinomas (65%) showed rare histotypes: four invasive mucinous adenocarcinomas (20% in IPF patients versus 1% in non-IPF controls, P = 0.002), seven tumours (35%) that were characterized by variable expression of markers of enteric differentiation, and two tumours (10%) that showed a peculiar basaloid component.
CONCLUSIONS: The immunohistochemical characterization of carcinomas arising in IPF patients shows striking divergence from that in non-IPF smokers. The prevalence of rare entities showing bronchiole-related markers is in line with the hypothesis that these tumours arise from transformed small airways in honeycomb lung areas where abnormal bronchiolar proliferation takes place.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  histotypes; idiopathic pulmonary fibrosis; immunohistochemistry; lung carcinoma

Mesh:

Year:  2017        PMID: 28556957     DOI: 10.1111/his.13269

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  10 in total

Review 1.  The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.

Authors:  Jessica Lawrence; Richard Nho
Journal:  Int J Mol Sci       Date:  2018-03-08       Impact factor: 5.923

Review 2.  Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management.

Authors:  Justin M Oldham; Harold R Collard
Journal:  Front Med (Lausanne)       Date:  2017-08-02

3.  Computed tomography patterns predict clinical course of idiopathic pulmonary fibrosis.

Authors:  Byoung Soo Kwon; Jooae Choe; Kyung Hyun Do; Hee Sang Hwang; Eun Jin Chae; Jin Woo Song
Journal:  Respir Res       Date:  2020-11-10

4.  Genomic analysis between idiopathic pulmonary fibrosis and associated lung cancer using laser-assisted microdissection: A case report.

Authors:  Yuko Iida; Yasuhiro Gon; Yoko Nakanishi; Yusuke Kurosawa; Yoshiko Nakagawa; Kenji Mizumura; Tetsuo Shimizu; Noriaki Takahashi; Shinobu Masuda
Journal:  Thorac Cancer       Date:  2021-03-30       Impact factor: 3.500

5.  PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Sissel Kronborg-White; Line Bille Madsen; Elisabeth Bendstrup; Venerino Poletti
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

Review 6.  Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges.

Authors:  Namrata Kewalramani; Carlos Machahua; Venerino Poletti; Jacques Cadranel; Athol U Wells; Manuela Funke-Chambour
Journal:  ERJ Open Res       Date:  2022-06-20

Review 7.  Comorbidities and Complications in Idiopathic Pulmonary Fibrosis.

Authors:  Esteban Cano-Jiménez; Fernanda Hernández González; Guadalupe Bermudo Peloche
Journal:  Med Sci (Basel)       Date:  2018-08-30

Review 8.  Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis.

Authors:  Paloma Millan-Billi; Candela Serra; Ana Alonso Leon; Diego Castillo
Journal:  Med Sci (Basel)       Date:  2018-07-24

Review 9.  Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.

Authors:  Beatriz Ballester; Javier Milara; Julio Cortijo
Journal:  Int J Mol Sci       Date:  2019-01-30       Impact factor: 5.923

10.  Carcinoid Tumorlets Co-Existing with Chronic Pulmonary Inflammatory Processes: Imaging Findings and Histological Appearances.

Authors:  Jun Wang; Shuai Ren; Yongkang Liu; Kai Guo; Xiao Chen; Zhongqiu Wang; Rong Chen
Journal:  Med Sci Monit       Date:  2020-09-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.